Cardiovascular side effects of anabolic-androgenic steroids;Kardiovaskuläre nebenwirkungen von anabol-androgenen steroiden

Herz

Volumn 31, Issue 6, 2006, Pages 566-573

  Kindermann, Wilfried ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b Institut für Sport und Präventivmedizin   (Germany)

Author keywords

Anabolic androgenic steroids; Cardiac death; Cardiovascular side effects; Left ventricular hypertrophy; Premature atherosclerosis

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROSTENEDIONE; CLOSTEBOL ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; NANDROLONE; NANDROLONE DECANOATE; PRASTERONE; TESTOSTERONE DERIVATIVE;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHLETE; BLOOD CLOTTING; BODY BUILDING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY OBSTRUCTION; DIASTOLE; DOPING; DRUG EFFECT; DRUG MISUSE; FATALITY; FIBRINOLYSIS; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE CONTRACTION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; PATHOGENESIS; PREVALENCE; SPORT; SUDDEN DEATH; THROMBOGENESIS; THROMBOSIS; TRAINING; VASCULAR ENDOTHELIUM; VASOSPASM;

ADULT; ANABOLIC AGENTS; ANIMALS; ATHEROSCLEROSIS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DIASTOLE; DOPING IN SPORTS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPOPROTEINS; MYOCARDIAL INFARCTION; RISK FACTORS; THROMBOSIS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 33750045712     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2856-0     Document Type: Article

References (113)

1. Alen M, Rahkila P, Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int J Sports Med 1985;6:139-44.
2. Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg 2001;34:1123-6.
3. Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res 2004;50:253-9.
4. Appell HJ, Heller-Umpfenbach B, Feraudi M, et al. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med 1983;4:268-74.
5. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism 1987;36:949-52.
6. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol 1994;44:171-4.
7. Bahrke MS, Yesalis CE, Brower KJ. Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child Adolesc Psychiatr Clin N Am 1998;7:821-38.
8. Baldo-Enzi G, Giada F, Zuliani G, et al. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism 1990;39:203-8.
9. Behrendt H. Effect of anabolic steroids on rat heart muscle cells. I. Intermediate filaments. Cell Tissue Res 1977;180:303-15.
10. Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone. Cell Tissue Res 1977;181:423-6.
11. Beutel A, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment on tonic and reflex cardiovascular control in male rats. J Steroid Biochem Mol Biol 2005;93:43-8.
12. Bowman S. Anabolic steroids and infarction. Br Med J 1990;300:750.
13. Breeder CE, Quindry J, Brittingham K, et al. The Andro project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000;160:3093-104.
14. Clasing D. Anabole Steroide-Einsatz im Sport. In: Clasing D, Hrsg. Doping und seine Wirkstoffe. Balingen: Spitta, 2004:84-96.
15. Cohen LI, Hartford CG, Rogers GG. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc 1996;28:176-9.
16. Colan SD, Sanders SP, MacPherson D, et al. Left ventricular diastolic function in elite athletes with physiologic cardiac hypertrophy. J Am Coll Cardiol 1985;6:545-9.
17. Collomp K, Le Panse B, Portier H, et al. Effects of acute salbutamol intake during a Wingate test. Int J Sports Med 2005;26:513-7.
18. Cunha TS, Moura MJ, Bernardes CF, et al. Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment. Hypertension 2005;46:1010-5.
19. D'Andrea A, Caso P, Severino S, et al. Effects of different training protocols on left ventricular myocardial function in competitive athletes: a Doppler tissue imaging study. Ital Heart J 2002;3:34-40.
20. De Piccoli B, Giada F, Benettin A, et al. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med 1991;12:408-12.
21. Di Bello V, Giorgi D, Bianchi M, et al. Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc 1999;31:514-21.
22. Dickerman RD, Schaller F, McConathy WJ. Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use. Cardiology 1998;90:145-8.
23. Dickerman RD, Schaller F, Prather I, et al. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 1995;86:172-3.
24. Dickerman RD, Schaller F, Zachariah NY, et al. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 1997;7:90-3.
25. Ebenbichler CF, Sturm W, Ganzer H, et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 2001;158:483-90.
26. Falkenberg M, Karlsson J, Örtenwall P. Peripheral arterial thrombosis in two young men using anabolic steroids. Eur J Vasc Endovasc Surg 1997;13:223-6.
27. Ferenchick G, Schwartz D, Ball M, et al. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 1992;303:78-82.
28. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses 1991;35:27-31.
29. Ferenchick GS. Association of steroid abuse with cardiomyopathy in athletes. Am J Med 1991;91:562.
30. Ferrer M, Encabo A, Marin J, et al. Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 1994;252:233-41.
31. Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology 1997;88:218-20.
32. Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 2001;125:253-5.
33. Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 2005;15:1-6.
34. Fisher M, Appleby M, Rittoo D, et al. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract 1996;50:222-3.
35. Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 1988;69:632-3.
36. Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Br Med J 1975;2:471-3.
37. Fröhlich J, Kullmer T, Urhausen A, et al. Lipid profile of body builders with and without self-administration of anabolic steroids. Eur J Appl Physiol 1989;59:98-103.
38. Furlanello F, Bentivegna S, Cappato R, et al. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J 2003;4:829-37.
39. George KP, Wolfe LA, Burggraf GW. The "athletic heart syndrome". A critical review. Sports Med 1991;11:300-30.
40. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991;151:1925-33.
41. Godon P, Bonnefoy E, Guerard S, et al. Myocardial infarction and anabolic steroid use. A case report. Arch Mal Coeur Vaiss 2000;93:879-83.
42. Goldstein DR, Dobbs T, Krull B, et al. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary a rteriograms. South Med J 1998;91:780-4.
43. Grace F, Sculthorpe N, Baker J, et al. Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport 2003;6:307-12.
44. Gunes Y, Erbas C, Okuyan E, et al. Myocardial infarction with intracoronary thrombus induced by anabolic steroids. Anadolu Kardiyol Derg 2004;4:357-8.
45. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003;24:344-51.
46. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004;34:513-54.
47. Haykowsky MJ, Teo KK, Quinney AH, et al. Effects of long term resistance training on left ventricular morphology. Can J Cardiol 2000;16:35-8.
48. Hislop MS, St Clair Gibson A, Lambert MI, et al. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 2001;159:425-32.
49. Huie MJ. An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc 1994;26:408-13.
50. Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA 1984;252:507-13.
51. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977;232:H381-5.
52. Kantor MA, Bianchini A, Bernier D, et al. Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exerc 1985;17:462-5.
53. Karhunen MK, Rämö MP, Kettunen R. Anabolic steroids alter the haemodynamic effects of endurance training and deconditioning in rats. Acta Physiol Scand 1988;133:297-306.
54. Karila TA, Karjalainen JE, Mantysaari MJ, et al. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003;24:337-43.
55. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993;158:346-8.
56. Kley HK. Anabole Steroide - pharmakologische Wirkung der Dopingmittel. In: Clasing D, Hrsg. Doping und seine Wirkstoffe. Balingen: Spitta, 2004:64-83.
57. Krieg A, Scharhag J, Albers T, et al. Cardiac tissue Doppler in bodybuilders with chronic abuse of anabolic steroids. Int J Sports Med 2006: in press.
58. Kuipers H, Wijnen JA, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med 1991;12:413-8.
59. Laroche GP. Steroid anabolic drugs and arterial complications in an athlete - a case history. Angiology 1990;41:964-9.
60. La Rosée K, Schulz A, Böhm M, et al. Kardiale Dekompensation eines Bodybuilders. Dtsch Med Wochenschr 1997;122:1586-90.
61. LeGros T, McConnell D, Murry T, et al. The effects of 17 alpha-methyltestosterone on myocardial function in vitro. Med Sci Sports Exerc 2000;32:897-903.
62. Lenders JW, Demacker PN, Vos JA, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med 1988;9:19-23.
63. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
64. Lisiewicz J, Fijalkowski P, Sankowski J. Ischemic cerebral stroke and anabolic steroids (case report). Neurol Neurochir Pol 1999;32:137-9.
65. Longhurst JC, Kelly AR, Gonyea WJ, et al. Echocardiographic left ventricular masses in distance runners and weight lifters. J Appl Physiol 1980;48:154-62.
66. Luke JL, Farb A, Virmani R, et al. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci 1990;35:1441-7.
67. Lyngberg KK. Myocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger 1991;153:587-8.
68. Maravelias C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett 2005;158:167-75.
69. Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998;98:256-61.
70. Martineau L, Horan MA, Rothwell NJ, et al. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992;83:615-21.
71. McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 1988;62:164.
72. Melchert RB, Herron TJ, Welder AA. The effect of anabolic-androgenic steroids on primary myocardial cell cultures. Med Sci Sports Exerc 1992;24:206-12.
73. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995;27:1252-62.
74. Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart 2002;88:342.
75. Mewis C, Spyridopoulos I, Kuhlkamp V, et al. Manifestation of severe coronary heart disease after anabolic drug abuse. Clin Cardiol 1996;19:153-5.
76. Millman RB, Ross EJ. Steroid and nutritional supplement use in professional athletes. Am J Addict 2003;12:Suppl 2: S48-54.
77. Mochizuki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Phys Sports Med 1988;16:108-14.
78. Morganroth J, Maron BJ, Henry WL, et al. Comparative left ventricular dimensions in trained athletes. Ann Intern Med 1975;82:521-4.
79. Nieminen MS, Rämö MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996;17:1576-83.
80. Nottin S, Nguyen LD, Terbah M, et al. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol 2006;97:912-5.
81. Obasanjo IO, Clarkson TB, Weaver DS. Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism 1996;45:463-8.
82. O'Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust 2001;174:203-4.
83. Palatini P, Giada F, Garavelli G, et al. Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol 1996;36:1132-40.
84. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006;38:644-51.
85. Parssinen M, Kujala U, Vartiainen E, et al. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000;21:225-7.
86. Pearson AC, Schiff M, Mrosek D, et al. Left ventricular diastolic function in weight lifters. Am J Cardiol 1986;58:1254-9.
87. Pelliccia A, Spataro A, Caselli G, et al. Absence of left ventricular wall thickening in athletes engaged in intense power training. Am J Cardiol 1993;72:1048-54.
88. Pesola MK. Reversibility of the haemodynamic effects of anabolic steroids in rats. Eur J Appl Physiol 1988;58:125-31.
89. Petersson A, Garle M, Granath F, et al. Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. Drug Alcohol Depend 2006;81:215-20.
90. Pilo R, Aharony D, Raz A. Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism. Thromb Haemost 1981;46:538-42.
91. Rämö P, Kettunen R, Timisjarvi J, et al. Anabolic steroids alter the haemodynamic effects of endurance training on the canine left ventricle. Pflügers Arch 1987;410:272-8.
92. Rämö P. Anabolic steroids alter the haemodynamic responses of the canine left ventricle. Acta Physiol Scand 1987;130:209-17.
93. Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc 1992;24:633-7.
94. Sachtleben TR, Berg KE, Elias BA, et al. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 1993;25:1240-5.
95. Sahraian MA, Mottamedi M, Azimi AR, et al. Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report. BMC Neurol 2004;4:22.
96. Salke RC, Rowland TW, Burke EJ. Left ventricular size and function in body builders using anabolic steroids. Med Sci Sports Exerc 1985;17:701-4.
97. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend 2006;81:11-9.
98. Tagarakis CV, Bloch W, Hartmann G, et al. Anabolic steroids impair the exercise-induced growth of the cardiac capillary bed. Int J Sports Med 2000;21:412-8.
99. Takala TE, Kiviluoma K, Kihlstrom M, et al. Effects of physical training, methandione and their combination on the lysosomal hydrolytic activities in dog heart. Int J Sports Med 1992;13:52-5.
100. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165-8.
101. Thompson PD, Sadaniantz A, Cullinane EM, et al. Left ventricular function is not impaired in weight-lifters who use anabolic steroids. J Am Coll Cardiol 1992;19:278-82.
102. Tischer KH, Heyny-von Haussen R, Mall G, et al. Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids. Z Kardiol 2003;92:326-31.
103. Trifunovic B, Norton GR, Duffield MJ, et al. An androgenic steroid decreases left ventricular compliance in rats. Am J Physiol 1995;268:H1096-105.
104. Urhausen A, Albers T, Kindermann W. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003;84:369-75.
105. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004;90:496-501.
106. Urhausen A, Hölpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 1989;58:633-40.
107. Urhausen A, Kindermann W. Sports-specific adaptations and differentiation of the athlete's heart. Sports Med 1999;28:237-44.
108. Van Baak MA, Mayer LH, Kempinski RE, et al. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000;32:1300-6.
109. Webb OL, Laskarzewski PM, Glueck CJ. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism 1984;33:971-5.
110. Yeater R, Reed C, Ullrich I, et al. Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids. Br J Sports Med 1996;30:11-4.
111. Yesalis CE, Bahrke MS. Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:25-35.
112. Zaugg M, Jamali NZ, Lucchinetti E, et al. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 2001;187:90-5.
113. Zuliani U, Bernardini B, Catapano A, et al. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 1989;10:62-6.